{"url":"https://lda.senate.gov/api/v1/filings/777ba724-e162-4656-b711-e7e09badb85a/","filing_uuid":"777ba724-e162-4656-b711-e7e09badb85a","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2022,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/777ba724-e162-4656-b711-e7e09badb85a/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Tracy Spicer","dt_posted":"2023-01-20T13:19:53-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"401 9th St. NW","registrant_address_2":"Suite 720","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":72111,"url":"https://lda.senate.gov/api/v1/registrants/72111/","house_registrant_id":35940,"name":"AVENUE SOLUTIONS","description":"Government representation","address_1":"401 9th St. NW","address_2":"Suite 720","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"AMY TEJRAL","contact_telephone":"+1 202-347-9848","dt_updated":"2026-01-30T17:55:20.768017-05:00"},"client":{"id":207526,"url":"https://lda.senate.gov/api/v1/clients/207526/","client_id":1004595,"name":"IOVANCE BIOTHERAPEUTICS, INC.","general_description":"Development and commercialization of immunotherapies","client_government_entity":false,"client_self_select":null,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-10-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Education around tumor infiltrating lymphocytes (TIL) cancer therapies; S. 3700/H.R. 6833, Affordable Insulin Now Act; Issues related to reauthorization of FDA user fee bills (H.R. 7667, Food and Drug Amendments of 2022; S. 4348 Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDSLA Act of 2022)), including accelerated approval and reimportation; Issues related to the Public Health Emergency; Issues related to the White House Cancer Moonshot initiative; Issues related to accelerated approval; CMS Medicare Hospital Inpatient Prospective Payment System (IPPS) and Long-Term Care Hospital (LTCH) Rates Proposed Rule for FY 2023; Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act; Executive Order Directing HHS to Explore Additional Actions to Lower Prescription Drug Costs","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":48260,"prefix":"ms","prefix_display":"MS.","first_name":"ELIZABETH","nickname":null,"middle_name":"MACDONALD","last_name":"BARNETT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":23462,"prefix":null,"prefix_display":null,"first_name":"TRACY","nickname":null,"middle_name":null,"last_name":"SPICER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}